Latest Ratios: P/E Ratio -0.4x · EV/EBITDA N/A · ROE -455.8%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $12M | $23M | $24M | $15M | $11M | $46M | — | — |
| Enterprise Value | $7M | $18M | $28M | $-15425 | $-1794477 | $22M | — | — |
| P/E Ratio → | -0.41 | — | — | — | — | — | — | — |
| P/S Ratio | 5.10 | 9.93 | 15.04 | 13.99 | 8.81 | 39.02 | — | — |
| P/B Ratio | 1.30 | 3.88 | 10.63 | 0.82 | 0.70 | 1.75 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.94 | 17.49 | -0.01 | -1.49 | 18.86 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 62.0% | 62.0% | 66.6% | 64.5% | 63.4% | 68.6% | 70.5% | 75.9% |
| Operating Margin | -767.0% | -767.0% | -1091.8% | -1353.4% | -961.7% | -706.7% | -668.0% | -1252.6% |
| Net Profit Margin | -812.3% | -812.3% | -1155.0% | -1329.1% | -944.6% | -639.0% | -666.2% | -1213.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -455.8% | -455.8% | -182.2% | -84.8% | -54.8% | -50.5% | -196.0% | — |
| ROA | -112.3% | -112.3% | -93.6% | -63.8% | -50.1% | -41.7% | -68.3% | -89.1% |
| ROIC | -347.4% | -347.4% | -277.0% | -353.2% | -324.4% | -260.5% | -229.9% | — |
| ROCE | -167.9% | -167.9% | -124.5% | -72.4% | -54.9% | -52.8% | -86.2% | -102.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.80 | 0.80 | 3.23 | 0.37 | 0.04 | 0.04 | 0.58 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.78 | 1.73 | -0.82 | -0.81 | -0.90 | -0.36 | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | -8.85 | -8.85 | -10.73 | -85.12 | -844.80 | -390.86 | -549.72 | -1129.06 |
Net cash position: cash ($9M) exceeds total debt ($5M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.53 | 4.53 | 0.93 | 7.59 | 9.25 | 15.15 | 1.34 | 6.25 |
| Quick Ratio | 2.95 | 2.95 | 0.58 | 7.37 | 8.96 | 15.02 | 1.29 | 6.12 |
| Cash Ratio | 2.55 | 2.55 | 0.40 | 7.11 | 8.48 | 14.65 | 1.15 | 5.77 |
| Asset Turnover | — | 0.11 | 0.13 | 0.04 | 0.07 | 0.04 | 0.14 | 0.07 |
| Inventory Turnover | 0.15 | 0.15 | 0.18 | 0.57 | 1.01 | 1.78 | 2.33 | 1.30 |
| Days Sales Outstanding | — | 98.14 | 109.42 | 33.68 | 23.44 | 26.07 | 44.24 | 32.83 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $2M | $1M | $769219 | $590208 | $590208 | $588078 | $588078 |
Clinical trial funding shortfall
According to recent market data, Femasys trades at a price-to-sales multiple of 5.00, a valuation that appears untethered from current earnings and relies entirely on the successful clinical de-risking of the FemBloc pipeline rather than the modest revenue generated by its existing diagnostic product portfolio.
The absence of meaningful P/E or EV/EBITDA multiples reflects the market's treatment of the firm as a binary developmental play. Investors should monitor whether this premium valuation can be sustained if clinical milestones are delayed, as the current price-to-sales ratio implies significant future growth that the diagnostic segment alone cannot support.
As reported in financial statements, Femasys has consistently posted negative ROIC figures, with the most recent quarterly data showing a -79.9% return, indicating that the company is currently destroying rather than compounding invested capital as it funds its high-cost R&D and clinical trial infrastructure.
The persistent negative returns on capital suggest that the company's current business model is not yet self-sustaining. This trend warrants further investigation into whether the eventual commercialization of the therapeutic pipeline can achieve the scale necessary to flip these returns into positive territory before the capital base is fully exhausted.
Based on Femasys's reported figures, the cash conversion cycle has exhibited extreme volatility, reaching 1139 days in 2026Q1, which suggests significant inefficiencies in inventory management and a potential disconnect between the company's sales efforts and its ability to convert those sales into actual cash flow.
The erratic nature of the CCC, driven by massive swings in days inventory outstanding, implies that the company may be struggling to align its production of diagnostic devices with actual end-user demand. This lack of operational efficiency places additional pressure on the company's already strained liquidity position.
According to the most recent quarterly filings, the current ratio has declined to 3.91 from significantly higher levels, signaling that the company's liquidity position is becoming increasingly vulnerable as it continues to burn through its cash reserves to support ongoing clinical development and specialized sales operations.
While the current ratio remains above 1.0, the rapid depletion of cash suggests that the company may face a liquidity crunch in the near term. Investors should monitor the company's ability to secure non-dilutive financing, as the current cash runway appears insufficient to reach the next major clinical milestone.
As indicated by the company's reported figures, the debt-to-equity ratio of 0.65 is frequently misapplied by analysts to assess solvency, which obscures the reality that Femasys is almost entirely reliant on dilutive equity financing rather than debt to sustain its high-cost R&D and clinical trial activities.
Using traditional leverage ratios for a clinical-stage company like Femasys is misleading because it ignores the 'hidden' cost of equity dilution. A more appropriate metric for this business model would be the 'cash burn rate' relative to the remaining cash runway, which provides a clearer picture of the company's true financial risk.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying FEMY stock.
Femasys Inc.'s current P/E ratio is -0.4x. This places it at the 50th percentile of its historical range.
Femasys Inc.'s return on equity (ROE) is -455.8%. The historical average is -170.7%.
Based on historical data, Femasys Inc. is trading at a P/E of -0.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Femasys Inc. has 62.0% gross margin and -767.0% operating margin.